Edrecolomab: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Edrecolomab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
(No difference)
|
Revision as of 20:20, 27 September 2011
Edrecolomab (MAb17-1A) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary studies had shown promise of a possible use in patients with colorectal carcinoma. However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents [1]. It is important to mention that edrecolomab was well tolerated and as such research has now concentrated on whether it can be of any use in other forms of cancer.